Preventing type 2 diabetes with low-dose combinations

The Lancet

Volumn 376, Issue 9735, 2010, Pages 72-74

  Buchanan, Thomas A ^a   Xiang, Anny H ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; METFORMIN; PLACEBO; ROSIGLITAZONE; TETRAHYDROLIPSTATIN;

DIARRHEA; HUMAN; INCIDENCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77955012604     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60900-2     Document Type: Note

References (11)

1. Tuomilehto J, Lindstrom J, Eriksson JG, et al, for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350 (Pubitemid 32378388)
2. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
3. Chaisson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, for the STOP-NIDDM Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077
4. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796-2803
5. DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: randomised controlled trial. Lancet 2006; 368: 1096-1105
6. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 2004; 27: 155-161
7. Buchanan TA. (How) Can we prevent type 2 diabetes? Diabetes 2007; 56: 1502-1507
8. The Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1477-1490
9. Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010; published online June 3. DOI:10.1016/S0140-6736(10)60490-4.
10. Hazzard WR, Crockford PM, Buchanan KD, Vance JE, Chen R, Williams RH. A double antibody immunoassay for glucagon. Diabetes 1968; 17: 179-186
11. Xiang A, Peters RK, Kjo SL, et al. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006; 55: 517-522